Who Owns Shenzhen Hepalink Pharmaceutical Group Co. Company?

Shenzhen Hepalink Pharmaceutical Group Co. Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Shenzhen Hepalink Pharmaceutical Group Co.?

Understanding Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s ownership is key for investors and stakeholders. The company, founded in 1998, has grown into a global biopharmaceutical leader, initially focusing on the heparin industrial chain.

Hepalink specializes in heparin sodium APIs and low molecular weight heparin preparations, expanding into innovative drugs. As of July 2025, it operates globally with over 1,900 employees and a market capitalization of approximately CN¥18.593 billion.

Who holds the reins at Shenzhen Hepalink Pharmaceutical Group Co.?

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 by Mr. Li Li and Mr. Yu Shan. These founders laid the groundwork for the company's focus on heparin purification and its subsequent growth. Their combined expertise and vision were key to the early development of the organization.

Founding Vision

The company's foundational vision centered on expertise in the heparin industrial chain. This included a focus on innovative drug development and ambitious global expansion plans.

Mr. Li Li's Background

Before co-founding Hepalink, Mr. Li Li held leadership roles at Chongqing Tongda Biological Products Co. Ltd. He also contributed to biochemical research at Chengdu Meat Processing Factory.

Mr. Yu Shan's Experience

Mr. Yu Shan's prior experience includes serving as General Manager at Shenzhen Yuanzheng Pharmaceutical Co., Ltd. This background provided valuable insights for Hepalink's strategic direction.

Corporate Governance

The company's Articles of Association, drafted according to Chinese law, govern share issuance and shareholder rights. Each share of the same class carries equal rights.

Registered Capital

The registered capital of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands at RMB1,467,296,204. Each share has a par value of RMB1.

Ultimate Control

Mr. Li Li and Ms. Li Tan are identified as the individuals who ultimately control the company. They act in concert to direct its operations and strategy.

While the precise initial equity distribution among the founders is not publicly detailed, the leadership roles and strategic contributions of Mr. Li Li and Mr. Yu Shan were fundamental to the company's establishment. Their early efforts in developing heparin purification technologies and building manufacturing capabilities set the stage for the company's future growth, as further detailed in the Brief History of Shenzhen Hepalink Pharmaceutical Group Co.

Early Ownership Structure

The ultimate control of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. rests with Mr. Li Li and Ms. Li Tan, who operate in concert. Specific details regarding early shareholding percentages or founder agreements are not readily available in public records.

• Founders: Mr. Li Li and Mr. Yu Shan
• Mr. Li Li's expertise: Heparin purification technologies
• Mr. Yu Shan's role: Manufacturing site development and corporate strategy
• Registered Capital: RMB1,467,296,204
• Ultimate controllers: Mr. Li Li and Ms. Li Tan

Shenzhen Hepalink Pharmaceutical Group Co. SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s ownership journey began in 1998, evolving significantly with its dual listings on the Shenzhen Stock Exchange in May 2010 and the Stock Exchange of Hong Kong in July 2020. These milestones expanded its shareholder base, incorporating both domestic and international investors.

As of July 21, 2025, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has 1.47 billion shares outstanding, with a market capitalization reaching approximately CN¥18.593 billion. The ultimate control of the company resides with Mr. Li Li and Ms. Li Tan, who operate in concert. While precise percentage holdings for all major stakeholders are not always publicly detailed, significant institutional investors include AVIC Trust Co., Ltd., State Street Global Advisors Ltd., and Invesco Great Wall Fund Management Co. Ltd., indicating a diverse ownership structure beyond the founders.

Key Financial and Ownership Insights

The company's financial performance and strategic decisions are crucial indicators of its ownership dynamics and future direction.

• As of March 28, 2025, the 2024 annual results reported revenue of approximately RMB5,258.9 million.
• Profit attributable to equity holders for 2024 was approximately RMB646.7 million.
• A proposed final cash dividend of RMB2.5 (tax inclusive) per ten ordinary shares was announced for 2024.
• Strategic expansion into CDMO services for large molecule biologics and innovative drugs is a key growth area.
• The company's focus on shareholder returns alongside expansion reflects its management's approach to value creation.
• Understanding the Growth Strategy of Shenzhen Hepalink Pharmaceutical Group Co. provides context for its ownership structure and investor appeal.

Shenzhen Hepalink Pharmaceutical Group Co. PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of March 31, 2025, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has a Board of Directors composed of both executive and independent non-executive members. Key figures include Mr. Li Li as Chairman and President, and Mr. Shan Yu as General Manager and Vice President, alongside Ms. Li Tan, who serves as Deputy General Manager and Executive Director. These individuals, particularly Mr. Li Li and Mr. Shan Yu, represent the company's co-founders and significant stakeholders.

The voting power within Shenzhen Hepalink Pharmaceutical Group Co., Ltd. generally follows a one-share-one-vote principle for all ordinary shareholders, encompassing both domestic A shares and overseas listed H shares. As of May 22, 2025, the total number of voting shares available was 1,467,296,204, with 1,247,201,704 A shares and 220,094,500 H shares. At the 2024 Annual General Meeting, held on May 22, 2025, approximately 60.20% of the total voting shares were represented. While specific details on dual-class shares or golden shares are not publicly prominent, the influence of Mr. Li Li and Ms. Li Tan suggests a significant concentration of voting power, indicating their substantial role in Shenzhen Hepalink ownership. Recent governance adjustments, effective March 31, 2025, saw Mr. Li Li step down from the Nomination Committee, with Ms. Li Tan appointed in his place. The Board operates with four key committees: Strategy, Audit, Remuneration and Evaluation, and Nomination, with board members actively participating in these groups, contributing to the overall governance and strategic direction of the Hepalink Pharmaceutical Group.

Board Governance and Shareholder Representation

The Board of Directors plays a crucial role in the governance of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Understanding their composition and the voting structure is key to grasping Hepalink Pharmaceutical Group Co Ltd shareholders' influence.

• Executive directors, including co-founders, hold significant positions.
• Independent non-executive directors provide oversight.
• Voting power is generally aligned with share ownership.
• Board committees manage specific areas of corporate governance.
• Recent changes reflect evolving board responsibilities, impacting Hepalink Pharmaceutical major investors.

Shenzhen Hepalink Pharmaceutical Group Co. Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Recent developments for Shenzhen Hepalink Pharmaceutical Group Co. have focused on global expansion and strategic partnerships, influencing its market position. The company's efforts to secure drug approvals and enter new distribution agreements are key to its ongoing growth trajectory.

The company's financial performance in 2024 showed a slight revenue dip but a substantial increase in gross profit, leading to a profitable year. This turnaround is supported by strategic initiatives and a proposed final cash dividend, indicating a positive outlook for shareholders.

Global Expansion Milestones

In April 2025, enoxaparin sodium injection received drug registration approval in South Africa. Further, EMA approved manufacturing of Inhixa at its Shenzhen facility in June 2025.

Strategic Market Partnerships

A partnership with Zhejiang Yongtai Pharmaceutical was established in January 2025 for distributing Gabapentin capsules in the US. These alliances are crucial for market penetration.

Market Valuation and Leadership

As of July 21, 2025, the stock price was $1.93 (USD) with a market capitalization of $2.59 billion. Co-founders Mr. Li Li and Mr. Yu Shan maintain leadership roles, ensuring continuity.

Supply Chain Resilience Focus

The company is diversifying heparin sourcing to include biosynthetic and bovine heparin. This strategy aims to mitigate supply chain risks and enhance operational stability.

Shenzhen Hepalink Pharmaceutical Group Co. Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔